Try our Advanced Search for more refined results
Life Sciences - July, 2024
297 articles
- Del. Justices Reject New Earnout Claim In $300M Deal Appeal
- 2nd Circ. Paves Way For Conn. Zantac Bellwether, Attys Say
- AI Prior Art Is Either Nothing New Or A Red Flag, USPTO Told
- Del. Judge Clears Lupin's Generic Kidney Disease Drug
- Novartis Says FDA Wrongly OK'd Generic Heart Drug
- Inhaler Patents 'Must Be' In Orange Book, Teva Tells Fed. Circ.
- How To Grow Marketing, Biz Dev Teams In A Tight Market
- 1st Circ. Mostly Backs $5M Award In Biotech Recruiting Spat
- 5 Trials To Watch In The 2nd Half Of 2024
- AIG Units Off Hook In Defending McKesson Opioid Suits
- Life Sciences Cases To Watch 2024: A Midyear Report
- 2024 Product Liability Areas To Watch
- Cook Medical Vein Filter Claims Came Too Late, 7th Circ. Says
- DC Circ. Finds NIH's Comment Restrictions Unconstitutional
- AIDS Org Sues Express Scripts For PBM Monopoly
- Judge Wants Device Warning Answers From Mich. Justices
- Chancery Rejects Forte-Camac Deal As 'Not Fair' To Class
- Psychedelics And The Law: A Midyear Review
- Patent Lessons From 5 Federal Circuit Reversals In June
- DOD Contractors Must Face Suit Over 'Made In U.S.A.' Label
- Unpacking HHS' Opinion On Cell Therapy Refund Programs
- Rock Climbing Makes Me A Better Lawyer
- Litigator Rejoins Faegre Drinker From Medical Device Co.
- What Mass. Attys Will Be Watching In The 2nd Half Of 2024
- Genzyme Says Sarepta's Dystrophy Gene Therapy Infringes IP
- Medical Co. Can't Get Alleged Fraudulent Arbitral Award Nixed
- NIST Lays Out 200+ Ways To Tackle Generative AI Risks
- Wash. Says At-Home Rape Kit Law Targets Harm, Not Speech
- Gilstrap Finds Nothing Between The Lines Of Barcode Patents
- Vaccine Co. Was Sanctioned For Deliberately Hiding Testing
- Boehringer Appeals HHS Win In Medicare Drug Price Suit
- Kirkland-Led Amulet Closes $1.2B Health-Focused Fund
- Think Like A Lawyer: Dance The Legal Standard Two-Step
- Alice Step 2 Trends Show Courts' Extrinsic Evidence Reliance
- Recent Settlement Shows 'China Initiative' Has Life After Death
- Legalization Org Taps Cannabis Atty As New Treasurer
- GSK Settles Ill. Zantac Cancer Suit
- Firm, Ex-Client Brief Conn. High Court In Punitive Award Case
- Catching Up With Delaware's Chancery Court
- DOJ Innovasis Settlement Offers Lessons On Self-Disclosure
- How Orange Book Antitrust Scrutiny Is Intensifying
- Ex-Pharma Exec Seeks Leniency After SEC Contempt Plea
- 'Low-Grade Lawyering': Quinn Emanuel Attys Draw Judge's Ire
- Apple Commits To White House Guidelines For Responsible AI
- Product Liability Cases To Watch 2024: A Midyear Report
- Weight-Loss Drugs May Spur Next Major Mass Tort
- Del. Court Won't Let Generic Co. Walk Back Invalidity Promise
- Indivior To Pay $86M To Settle Opioid Claims By 5 States
- Hearing Set Over Bid To Recuse Judge In Philly Zantac Cases
- UK Litigation Roundup: Here's What You Missed In London
- 3rd Circ. Again Tosses J&J Talc Unit's 'Texas Two-Step' Ch. 11
- Seattle, Monsanto Ink $160M Deal Over PCBs In Duwamish
- Pfizer Calls GSK Patents In COVID Vax Case Unenforceable
- DC Panel Upholds FDA's Win Against Ipsen's Generics Suit
- Shkreli Says He Has Right To Use Wu-Tang Clan Album Copies
- Ex-Pharma Exec's Counsel Accused Of Reading Stolen Emails
- Loeb & Loeb Says Ex-GC's Sanctions Motion Is Bogus
- Deals Rumor Mill: Wiz-Google, Daily Telegraph, Medline IPO
- Clinic Drops Case Against Maker Of Body-Sculpting Devices
- Rite Aid's Elixir Buyer Must Pay Additional $50M In Ch. 11 Sale
- The FTC Needs To Challenge The Novo-Catalent Deal
- After Chevron: Slowing Down AI In Medical Research
- Patent Cap In Drug Pricing Bill Seen As Having Muted Effect
- McCarter & English Beats Biotech Malpractice Suit In NJ
- Ex-Pharma Exec Gets Jail For Insider Trading On Kodak Loan
- Priest Loses Fee Bid After 'Split Baby' SEC Verdict
- Being A Luthier Makes Me A Better Lawyer
- Meet The Lead Ozempic Lawyers
- Wash. AG Says 'Abortion Reversal' Clinic's Suit Still Deficient
- $680M Allergan FCA Suit Tossed After High Court Revival
- Invitae's Ch. 11 Plan Needs Tweaking, Judge Says
- 4th Circ. Says Bad Jury Instructions Gave J&J Win In Mesh Suit
- Ex-Celgene Exec Off The Hook For Statements To Investors
- Feds Urge 6th Circ. To Affirm Pharma Owner's Fraud Sentence
- Chancery Slams 'Squishy' Deal In 'Tagalong' BioMarin Suit
- Split 2nd Circ. Keeps Zantac Suits In Conn. State Court
- FDA's Multifaceted Role On Display In MDMA Therapy Scrutiny
- Lead Like 'Ted Lasso' By Embracing Cognitive Diversity
- Senate Dems Roll Out Bill To Codify Chevron Deference
- 4 Firms Guide SPAC Mergers Targeting AI, Cannabis Sectors
- GSK Inks $4.5M Deal Resolving 'Non-Drowsy' Robitussin Suit
- AbbVie Challenges Mo. Drug Discount Program Requirements
- USPTO Wins Dismissal Of Danish Co.'s PTSD Drug Lawsuit
- Tevra Says Bayer Owes Millions As Antitrust Trial Opens
- Allarity Warns Of SEC Suit Over Cancer Drug Statements
- Michigan's Cases To Watch 2024: A Midyear Report
- Price-Fixing Claims Against Par Pharma On Chopping Block
- How Cos. Should Handle Research Org.'s Carcinogen Evals
- DuPont, NC To Drop Docs Dispute In 'Forever Chemicals' Case
- Groups Ask 3rd Circ. To Reverse Medicare Drug Price Rulings
- Anthem Blue Cross Wants Lab's $3.8M Suit Tossed
- 1st Circ. Hints At Higher Bar For Feds In Anti-Kickback Cases
- Lack Of 'Smoking Gun' Sinks J&J's Bid To DQ Beasley Allen
- Catching Up With Delaware's Chancery Court
- Jazz Says Narcolepsy Drug Charge MDL Should Be Tossed
- House IP Committee Heads Unveil Drug Pricing Bill
- Splenda Must Face False Ad Suit Over Diabetes Benefits
- Conn. Hospital Didn't Heed Insulin Pen Warnings, Maker Says
- Boehringer Looks To Toss Inhaler Antitrust Case
- Boehringer Long Ignored Zantac's Cancer Signs, Jury Hears
- Amazon Gets Tainted Eye Drop Suit Pared Down
- A Guide To The USPTO's Long List Of Requests For Comment
- McCarter & English Pushes To End Biotech Malpractice Row
- Gout-Focused Biotech Raises $60M In Latest Funding Round
- Analyzing FDA Draft Guidance On Clinical Trial Diversity
- Ex-Pharma Sales Exec Denies Fake Prescription Scheme
- Regeneron Rips DOJ's FCA Suit As 'Divorced From Reality'
- Cooley, Latham Lead Biotech Firm Artiva's Upsized $167M IPO
- What's New In The AI Healthcare Regulatory Space
- Del. Dispatch: 27.6% Stockholder Not A Controller
- DaVita To Pay $34M In Medicare Kickback Whistleblower Suit
- Abbott Wins Trust Asset Freeze To Collect $33M In TM Fight
- Apple Wants 2 Trials In Masimo Trade Secrets And Patent Row
- Vidal Backs 'Egregious Abuse' Findings Against Vaccine Maker
- Biopharma Shareholder Sues In Del. For Docs On Akeso Deal
- LegitScript Asks 9th Circ. To Ax Price-Checker Antitrust Suit
- Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
- GSK, Boehringer Face Jurors Again On Zantac Cancer Claims
- Docs Get Same Hefty Opioid Sentences Despite Top Court Win
- Pharma Biz Buys Animal Medicine Co. For Up To $520M
- Ga. Mineral Co. Can't Nab Win In Row Over Talc Suit Coverage
- PharMerica Inks $100M Deal In 13-Year-Old Whistleblower Suit
- ITC Affirms Lab Equipment Co.'s Patent Wasn't Infringed
- Many AI Patent Eligibility Issues Still Hazy After Guidance
- Pharma Co. Slams Magistrate's Venue Report In Opioid Suit
- Chancery Again Spikes Biopharm Board Pay Deal, $600K Fee
- Hospital Trims Its Insulin Pen Claims Against Novo Nordisk
- Ex-Genentech Worker Seeks Revival Of 401(k) Investment Suit
- 3 Policyholder Tips After Calif. Ruling Denying D&O Coverage
- 1 Year At The UPC: Implications For Transatlantic Disputes
- Boehringer Wants Inhaler Antitrust Case Moved To Mass.
- Bruised SPAC Market Pins Revival Hopes On Veteran Backers
- Now More Than Ever, Lawyers Must Exhibit Professionalism
- ADA Can't Shield Worker From Failed Drug Test, Co. Says
- Gilead Asks Calif. Supreme Court To Ax 'Disastrous' Decision
- UPC Knocks Out Amgen's Cholesterol Drug Patent
- Chancery Orders Illumina Docs Released In Grail Merger Fight
- Tycoon's Pilot Says Feds' Stock Tip Claims Don't Add Up
- FDA Vet Joins Arnold & Porter As Counsel On Healthcare
- Drugmaker BioLineRx Beats Investor Suit Over Cash Shortfall
- 3rd Circ. Backs Tossing Over 1K Suits In Merck Vaccine MDL
- High Court Made Profound Mistake In Tossing Purdue Deal
- Manatt Adds Healthcare Transactions Partner From McDermott
- Heart-Focused Biotech Closes $260M Series B Funding Round
- Ex-CBD Exec Gets $533K In Fla. Investment Fraud Suit
- Vertex Pharma Widens War On Watchdog's Kickback Views
- The 2024 Diversity Snapshot: What You Need To Know
- These Firms Have The Most Diverse Equity Partnerships
- Serving In The National Guard Makes Me A Better Lawyer
- Big Business May Come To Rue The Post-Administrative State
- Acuitas Seeks Credit For IP Tied To COVID Vax
- Ex-Pfizer Worker Seeks No Time For Paxlovid Insider Trading
- Walgreens Investor Sues Over Challenged Pharmacy Division
- AbbVie Can't Keep CoolSculpting Suit In NJ Fed Court
- Theranos Ex-Exec's Lead Atty Joins Boutique Firm In LA
- Proposed Terminal Disclaimers Rule Harms Colleges, Startups
- Catching Up With Delaware's Chancery Court
- Health Services Spinoff Leads 3 IPO Launches Totaling $1.1B
- A Midyear Forecast: Tailwinds Expected For Atty Hourly Rates
- Law360 Names 2024's Top Attorneys Under 40
- Del. Court Finds 1 Of 6 Bylaws Invalid But All Unenforceable
- AI Drugmaker BioXcel Beats Investor Fraud Suit, For Now
- Whistleblower's Attys Get $5.9M After Losing $11.5M Fee Ask
- Opioid MDL Plaintiffs Atty Fee Awards Upheld
- Plaintiffs Want Opioid MDL Bellwethers Cut For Lost Emails
- Fed. Circ. Upholds Natera's Injunction In Cancer Test IP Fight
- Fed. Circ. Probes Case With Apple Watch Import Ban At Stake
- Judge Denies Go-Ahead For Suit Over Invitae Refi Deal
- No Injury In Suit Targeting J&J Asset Shuffles, Talc Unit Says
- Zimmer Biomet Owes Despite Expired Patents, 7th Circ. Says
- Chancery Tosses Centene Shareholders' Medicaid Fraud Suit
- Widower Drops Suit Over Surgical Robot-Related Death
- Ex-Quantix Worker Sues Abbott Labs Over Drug Test Firing
- AbbVie Brings Atty-Client Privilege Fight To Supreme Court
- Ex-Magellan Execs Waive Conflicts Over Past Shared Counsel
- Senate Clears Patent Bill Aiming To Lower Drug Prices
- Pfizer's $50M EpiPen Deal Gets Final OK In Antitrust Suit
- IP Forecast: Napa Winery's Ex-Atty Wants Another Trial
- Judge Won't Dismiss Cannabis Extraction IP Dispute
- DC Judge Questions Pharma Co.'s Generic Harm In FDA Spat
- Fed. Circ. Pauses Ouster Of Teva Patents From Orange Book
- Critical Questions Remain After High Court's Abortion Rulings
- Opiate MDL Judge Flags Evidence Preservation Shortfall
- A Look At Acquisition Trends For Radiopharmaceuticals
- GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals
- States Should Loosen Law Firm Ownership Restrictions
- Talc Law Firms Beat J&J Subpoenas Seeking Funding Info
- Deals Rumor Mill: Saudi Aramco, Paramount Global, Carlyle
- Orrick Adds Wilson Sonsini, Hooper Lundy Healthcare Attys
- Patent Cases To Watch In The Second Half Of 2024
- Roundup Cancer Case Revived By Oregon Appellate Panel
- Drug Pricing, Overreach Dominate IP Disclaimer Feedback
- Medical Imaging Co. Looking To Vacate 'Tainted' Award
- GOP Bombards Agencies With Demands After Chevron's End
- Meijer Says Takeda Can't Force Antitrust Suit Into Arbitration
- Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud
- Buyers Say Teva Had Multipart Scheme To Delay Inhaler Rivals
- Navigating FDA Supply Rule Leeway For Small Dispensers
- RJ Reynolds Urges Toss Of Menthol Suit Against FDA
- Ex-FDA Regulator Joins Chicago Boutique Amin Wasserman
- Longtime Axinn Atty To Chair Polsinelli's Hatch-Waxman Team
- Solving Puzzles Makes Me A Better Lawyer
- Ex-CEO Convicted In COVID Test Kit Fraud Case
- Pharma Co. Fined $16.9M For Fake Scripts, Ex-VP Arrested
- Bard Fights 'Patent Misuse' Ruling In $53M Suit At 9th Circ.
- South Africa Drops J&J Probe After TB Drug Price Cuts
- Fla. Judge Won't Nix Antitrust Claims Against Alcon
- HEC Can't Get Damages Over Injunction In Novartis Feud
- BCBS Unit Fails To Stop Religious Vaccine Objector Suits
- 3rd Circ. Rips 2nd Circ. In Asset Freeze Ruling For SEC
- NJ Panel Revokes Coverage For Pharma Co. In Fraud Row
- Purdue Plans 'High-Speed' Bid For New Ch. 11 Plan
- NJ Jury Begins Deliberating COVID Test Kit Fraud Case
- Terrorism Victims Push To Keep Pharma Suit In DC Circ.
- FTC Says Drug Middlemen Inflate Costs, Squeeze Pharmacies
- Gov't Missed Merck Vax Potency Problem, 3rd Circ. Told
- Texas Ethics Opinion Flags Hazards Of Unauthorized Practice
- 6 Lessons From DOJ's 1st Controlled Drug Case In Telehealth
- After Chevron: Scale Tips Favor Away From HHS Agencies
- Emergent, J&J Reach $50M Deal In COVID Vax Supply Fight
- Biotech Slaps Intellia With IP Suit Over $100M Regeneron Deal
- Jurors Told To Decide Who Is Lying In COVID Test Fraud Case
- Blank Check Co. Sagaliam Gets Shareholder Suit Trimmed
- Purdue Creditors Look To Sue Sacklers After Justices' Ruling
- Biotech Co. Alleges Arbitrator Conflict In Patent Award Fight
- Ex-Ga. Insurance Chief Wants Lighter Term In Kickback Case
- Kirkland, Fenwick Steer Lilly's $3.2B Morphic Acquisition
- 2 Options For Sackler Family After High Court Purdue Ruling
- In Memoriam: The Modern Administrative State
- After Chevron: Expect Limited Changes In USPTO Rulemaking
- Rite Aid Says Elixir Buyer In Contempt Over Liability Dispute
- Catching Up With Delaware's Chancery Court
- The Biggest Patent Rulings Of 2024: A Midyear Report
- How Reshaped Circuit Courts Are Faring At The High Court
- Breaking Down The Vote: The High Court Term In Review
- The Sharpest Dissents From The Supreme Court Term
- High Court Flexes Muscle To Limit Administrative State
- 5 Moments That Shaped The Supreme Court's Jan. 6 Decision
- The Funniest Moments Of The Supreme Court's Term
- 2024 Global M&A, Mega-Deal Values Outpacing 2023
- The Firms That Won Big At The Supreme Court
- Novartis Allegedly Sat On Drug Rights To Avoid $1B Payment
- How High Court Approached Time Limit On Reg Challenges
- 3rd Circ. Preview: Ponzi Scheme, Merck Vaccine Heat Up July
- Fed. Circ. Skinny Label Ruling Guides On Infringement Claims
- Top Federal Tax Cases To Watch In The 2nd Half Of 2024
- A&O Shearman-Led GSK Signs €1.4B Deal For Vaccines
- 4 Takeaways From Biotech Patent Invalidity Ruling
- How To Clean Up Your Generative AI-Produced Legal Drafts
- HHS Scores Early Win In Boehringer's Medicare Pricing Suit
- Humana Drops 6th Circ. Remand Bid In Ohio Collusion Suit
- Roche Says Stanford Profs Stole Cancer Detection Tech
- Revived Skinny Label Case Is A Warning For Generics
- Appeals Board Tosses Revived License Breach Dispute
- Calif. Ruling Heightens Medical Product Maker Liability
- Cooley DQ'd From IP Case Over Atty's Past Patent Work
- Constitutional Protections For Cannabis Companies Are Hazy
- Penile Implant Doc Seeks $7M Atty Fees, Costs In $18M IP Win
- 4 Mass. Rulings You Might Have Missed In June
- 1st Circ. Hands Hearing Loss Biotech Win In Stock-Drop Suit
- Cerevel Investors Allege Insider Trades Pre-$8.7B AbbVie Deal
- USPTO Disclaimer Rule Would Complicate Patent Prosecution
- After Chevron Deference: What Lawyers Need To Know
- Chancery Tosses Challenge To $3B AstraZeneca Viela Bio Sale
- Quest Diagnostics Paying $985M For OMERS' LifeLabs
- Boxing Makes Me A Better Lawyer
- FTC Investigating Teva Inhaler Patent Listings, Report Says
- Chamber, Pharma Slam Colorado Drug Price Controls
- Biotech Biz Co-Directors Sue Each Other In Del., Cite Breaches
- Purdue Ch. 11 Ruling Reinforces Importance Of D&O Coverage
- Pharma Co. Scores Exit In Investor Suit Over Primate Imports
- McKinsey Wants To Arbitrate Ex-Partner's Defamation Suit
- Beasley Allen Slams J&J's DQ Bid 'Check-Up' In Talc Tort
- Industry Self-Regulation Will Shine Post-Chevron
- 3 Ways Agencies Will Keep Making Law After Chevron
- After Chevron
- High Court Agrees To Review FDA's Flavored E-Cig Denial
- High Court's 1-2 Punch Sets Up Long-Standing Regs For KO
- UC Riverside Profs Win Combined $6.1M In Retaliation Trial
- State AGs Get Stay Lifted In Generic Drug Pricing Litigation
- IPO Rebound Leads Capital Markets Recovery At Midyear
- Caribou Bio Inks $3.9M Deal In Investors' Cancer Therapy Suit
- NJ Judge Tosses J&J Unit's Libel Claim Over Talc Study
- After Chevron: Expect Few Changes In ITC Rulemaking
- Bard, Hernia Mesh Claimants Can't Hide Injury MDL Deal Info
- 6 PTAB Events To Know From The Last 6 Months
- Talc Victims Can't Block J&J From Filing For Ch. 11 Outside NJ
- GSK Wants Lab's Zantac Whistleblower Suit Moved To Florida
- Atty Well-Being Efforts Ignore Root Causes Of The Problem
- Parsing Justices' Toss Of Purdue's Controversial Ch. 11 Plan
- Catching Up With Delaware's Chancery Court
- Manatt Managing Partner Begins Second 5-Year Term
- Apple Scores Some Patent Board Reviews In Watch IP Fight
- AbbVie Hit With Age, Gender Bias Suit By Former Salesman
- Ardian Raises $3.2B For 6th Co-Investment Fund
- Feds Say Ex-Magellan Officer's Atty May Have Conflict
- Supreme Court Widens Window To Challenge Federal Regs